Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 18.76% is 443% above its 3-year average of 3.46%, near the low end of its 3-year range (0.00%–92.00%).
6.99% above its 12-month average of 17.53%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 49.63%.
GROSS MARGIN
18.76%
GROSS MARGIN AVG TTM
17.53%
GROSS MARGIN AVG 3Y
3.46%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+6.99%
CURRENT VS 3Y AVG
+442.52%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.44%
median of 789 covered companies
CURRENT VS SECTOR MEDIAN
-53.61%
vs the sector median at left
Bullfrog AI Holdings, Inc. Common Stock
Market Cap
$12.05M
Gross Margin
18.76%
TTM Avg
17.53%
3Y Avg
3.46%
5Y Avg
0.00%
Market Cap
$12.12M
Gross Margin
36.23%
TTM Avg
36.65%
3Y Avg
39.59%
5Y Avg
41.13%
Market Cap
$12.51M
Gross Margin
-137.55%
TTM Avg
-73123.88%
3Y Avg
-36779.95%
5Y Avg
-24519.97%
Market Cap
$11.56M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$12.77M
Gross Margin
71.61%
TTM Avg
70.70%
3Y Avg
67.95%
5Y Avg
69.37%
Market Cap
$11.24M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$12.90M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bullfrog AI Holdings, Inc. Common Stock (BFRG) | $12.05M | 18.76% | 17.53% | 3.46% | 0.00% |
| IRIDEX Corporation (IRIX)vs › | $12.12M | 36.23% | 36.65% | 39.59% | 41.13% |
| Dare Bioscience, Inc. (DARE)vs › | $12.51M | -137.55% | -73123.88% | -36779.95% | -24519.97% |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.56M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lantern Pharma Inc. (LTRN)vs › | $12.60M | 0.00% | 0.00% | 0.00% | 0.00% |
| Biofrontera Inc. (BFRI)vs › | $11.39M | 84.45% | 64.39% | 56.15% | 53.94% |
| Cytosorbents Corporation (CTSO)vs › | $12.77M | 71.61% | 70.70% | 67.95% | 69.37% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.24M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.90M | 0.00% | 0.00% | 0.00% | 0.00% |
| Passage Bio, Inc. (PASG)vs › | $12.95M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
18.8%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 49.63% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 18.43% |
| 2025-06-30 | 19.61% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 92.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 92.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |